Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Ketamine Therapy
Psychedelic therapies are transforming our approach to mental health challenges, and two of the most highly talked about modalities are ketamine and psilocybin mushrooms. While both drugs can ultimately lead to significant changes in personality and cognition, they act via different neurochemical mechanisms and therapeutic paradigms. Whether you’re working with ketamine microdose, microdosing mushrooms, or full-dose treatments, it’s essential to know how they differ in onset, duration, and experiential quality. This guide walks you through how they work, dosing methods, safety considerations, and practical factors to help you determine which option most aligns with your goals.
Mechanistically, ketamine is an antagonist at NMDA glutamate receptors, leading to a glutamate release cascade and enhanced AMPA receptor activation. Such rapid neurochemical changes improve synaptic plasticity, frequently leading to mood enhancement within hours of taking it. By contrast, psilocybin, converted into psilocin in the bloodstream, primarily activates receptor-mediated (5‑HT₂A) serotonin signaling, resetting large-scale brain networks and leading to profound internal states of reflection. Although the ketamine dissociative state lasts only under an hour, psilocybin trips occur over several hours, with aftereffects that can last days or weeks.
Microdosing has increased in popularity as a way to tap into low-key benefits without totally psychedelic immersion. With psilocybin, a microdose is considered to be between 0.1 and 0.3 grams of dried mushroom (approximately 1–3 mg psilocybin) taken every three to four days, often in conjunction with intention-setting rituals for what some refer to as joyous microdosing. Ketamine microdosing protocols are less established, but usually consist of low oral or sublingual doses around 10 to 20 mg, monitored by clinical professionals. In contrast, full-dose ketamine treatments (infusions or nasal spray) take place in medical clinics over 30–60 minutes, and psilocybin ceremonies need a supportive environment for a 4‑6 hour period with preparatory and integration periods.
Therapies for both ketamine and psilocybin also focus on combining pharmacology with psychotherapy. In KAP, patients are first medically and psychologically evaluated, followed by a supervised ketamine session. This is carried out through a session, where the therapist gently holds space for the patient as they encounter dissociative states, with immediate debriefing and then continued integration work to apply what has been learned. Psilocybin-Assisted Therapy is structured around a similar three-phase model: preparatory meetings to set intentions, guided dosing sessions, and integration sessions to translate visionary content into real-world change. These frameworks highlight the need for professional guidance in psychedelic therapy.
One of ketamine’s most appealing characteristics is its speed of action: many people experience significant relief of depressive symptoms within two hours of a single infusion, with effects lasting one to two weeks. Psilocybin’s effects come on more slowly, with mood boosts and decreased anxiety, usually clear days after a session, and enduring personality changes like increased openness, which are reported months later. The rapid turnaround of a ketamine infusion makes it well-suited for crisis intervention or severe treatment-resistant depression. At the same time, the hours-long immersive experience of psilocybin facilitates deep emotional processing and sustainable psychological growth.
Both treatments have excellent safety records when administered under expert care. Ketamine’s immediate side effects, including dissociation, high blood pressure, nausea, and dizziness, are generally monitored and treated in a clinical setting. Over-use, long-term use, or high-frequency use without supervision can, however, irritate the bladder and contribute to dependency. Psilocybin is physiologically benign but can induce vast emotional experiences or transient anxiety (“bad trips”) without sufficient support. Contraindications must be stringently screened to mitigate risks for both modalities, therapeutics must remain available during the dosing period, and comprehensive integration is required.
It is prescribed legally off-label for depression and PTSD in many countries, and Spravato (esketamine) nasal spray is federally approved by the US FDA for treatment-resistant depression. Other forms of ketamine, intravenous infusions, injections, and compounded lozenges are commonly used off-label under medical supervision. Psilocybin, on the other hand, is still listed as a Schedule I substance in most places, meaning that it can usually only be accessed in research studies or select retreat programs. With changing regulatory attitudes, expanded access to psilocybin therapy may be on the horizon; however, under the existing legal landscape, practitioners and patients must work within the confines of either (1) enrolment in clinical trials or (2) Cognitive Rehabilitation therapy settings.
.png)
Both ketamine and psilocybin are worth something in the context of the acute dosing session; they are truly valuable when those experiences are integrated into everyday life. Integration is guided reflection, usually through writing, therapy, or group work, that allows new insights to become embedded, behaviour to change, and ongoing mental health progress to be solidified. For ketamine, that might mean incorporating dissociative revelations into coping strategies for depression or PTSD. For psilocybin, it means deciphering visionary material. You can think of it as becoming adept at reading a book written in a foreign language and building up new emotional resilience; patients who do so have more durable therapeutic responses from both modalities.
Whether to choose ketamine or psilocybin also depends on therapy goals, personal preferences, and logistical factors. Ketamine’s rapid efficacy makes it the go-to treatment in cases of acute suicidality or severe treatment-resistant depression. Psilocybin’s long, introspective sessions are better for those seeking deep emotional healing, spiritual insights, or personality transformation. Microdosing provides a milder alternative for people who want slight improvements in mood and creative abilities without intense, all-consuming trips. Ultimately, working with experienced providers ensures that treatment plans, they microdosing mushrooms, ketamine microdose, or full-dose sessions, are individualised to maximise safety and therapeutic benefit.
Outside of Spravato, ketamine for depression is not an FDA-approved use of an anesthetic. These compounded ketamine formulations are not FDA-approved drugs. Psilocybin is investigated and has not been approved by the FDA. Speak to a licensed medical professional before beginning any psychedelic treatment.
Both ketamine and psilocybin mushrooms have a lot to offer in the way of therapeutic effects, but also have somewhat different strengths. Ketamine’s fast, glutamate-focused effect can save lives during a crisis, and psilocybin’s serotonin-governed experiences can bring profound emotional breakthroughs. From guided microdosing of mushrooms and ketamine microdose protocols to fully supported, immersive sessions, these therapies provide varied routes to healing. By having insight into their mechanisms of action, dosing protocols, safety profiles, and therapeutic paradigms, you’ll be equipped to make the best choice for your mental health journey.
All set to learn about personalised psychedelic care? Visit Isha Health to book your consultation now.
Some experimental therapies consider combining ketamine and psilocybin, but this practice is rare and uncommon to study. This is only to be done under professional monitoring.
Psilocybin mushrooms are naturally occurring fungi, while ketamine is a synthetic compound initially created as an anesthetic.
Mushroom micro-dosing has fewer side effects for some individuals, but safety depends on the user, dosage, and setting. Research consistently showed that mushroom microdosing benefits are primarily from placebo effects. Both alternatives are complex and will require professional assistance.
.png)
.png)
.png)
This website has been reviewed by Isha Health California, P.C. and should not be used as medical advice in place of a licensed psychiatric clinician.
IN CASE OF EMERGENCY:
If you are in a life-threatening situation, don’t use this site. Call, text, or chat 988 or 1-800-273-TALK (8255), or use these resources to get immediate help.
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.jpg)
.png)
.jpg)
.png)
.png)
.jpg)
.png)
.png)
.png)
.png)
%202.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
